Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Published:2022-03 Issue:3 Volume:7 Page:245-253
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Meng Xiangrui,Wu Tao,Hong Yonggui,Fan Qingxia,Ren Zhonghai,Guo Yanzhen,Yang Xiuli,Shi Pei,Yang Jiamei,Yin Xianzhe,Luo Zhiquan,Xia Jin,Zhou Yue,Xu Mengli,Liu Enjie,Jiang Guozhong,Li Shenglei,Zhao Feng,Ma Chi,Ma Chuanxiang,Hou Zhiguo,Li Jing,Wang Junsheng,Wang Feng

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference32 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Screening for esophageal squamous cell carcinoma: recent advances;Codipilly;Gastrointest Endosc,2018

3. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends;Van Rossum;Nat Rev Gastroenterol Hepatol,2018

4. SEER Cancer Statistics Review, 1975–2017;Howlader,2020

5. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;Kato;Lancet Oncol,2019

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09

2. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial;Med;2024-09

3. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study;European Journal of Cancer;2024-09

4. Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial;BMC Medicine;2024-08-26

5. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions;Expert Review of Clinical Immunology;2024-06-17